Core point 1. In the past three years, China's medical beauty industry has undergone earth-shaking changes, and non-surgical products occupy the mainstream 2. The brand is a marketing tool and a social contract for the legal entity to face society. Last year, it began to issue documents on supervising medical aesthetics, focusing on doctors' qualifications, marketing, and the capabilities of three types of ...
First, under the optimization of epidemic prevention, the repair market of damaged plates in the early stage, such as biomedical, aviation, wine travel and other plates; Second, under the demand of stable growth, the industry policy margin is loose, such as the real estate industry chain and the Internet and other industries; Third, under the theme of security for a long time, energy security, self contro...
Fosun Pharma’s Q3 net profit increased by 41.62% year-on-year, and a total of 9.7 million doses of the mRNA new crown vaccine Fubitai® were administered $復星医薬(02196.HK)$Fosun Pharma (02196.HK) yesterday disclosed the third quarterly report data, Q3 company revenue was 10.095 billion yuan, a year-on-year increase of 25.03%; net profit was 1.082 billion yuan, a year-on-year increase of 41.62%. The growth of Fosun Pharma’s performance is due to alleviation of the pressure of centralized procurement and price reduction of stock varieties. According to the announcement, as of October 24, Fosun Pharma’s Fubitai (mRNA Covid-19 vaccine) has been vaccinated in Hong Kong, Macau and Taiwan over 9.7 million. Agent. Article excerpted from the U.S. Stock Intelligence Agency
$復星医薬(02196.HK)$Musk: The future of medicine is mRNA. Basically you can cure everything with mRNA, it's like a computer program that you can program to do whatever you need to do. You can actually turn into a butterfly. We added fosun Pharmaceutical today. Because I want to be a butterfly
$キュアバック(CVAC.US)$$復星医薬(02196.HK)$Yesterday, Company C announced that it was suspending contracts with manufacturers because peak demand for vaccines had passed, which may have contributed to the sharp drop in vaccine stocks. Careful thought, and, yes, mostly the dozen vaccine, countries don't have the money waiting to donate hate, so several head vaccine company, some actual combat has been reviewed, some also not practical to review, rich have reserves more vaccine, really late development of vaccines can only drink soup, unless all vaccine failure now, must never again, Otherwise, the enthusiasm and difficulty of rer&d will be greater. The failure of C Company is the best proof.
1
報告
Virushunter :
They only cancelled contract with two smaller companies while retaining contracts with Norvartis and Bayer and two others. I think they are cuting costs for longer run.
Shanghai Fosun Pharmaceuticalに関するコメント
Techs slid as the market continued to be watchful of the Sino-US relations:
$阿里巴巴集団(09988.HK)$ dived 3.2% to $84.1.
$テンセント(00700.HK)$ sank 1.9% to $338.4.
$美団点評(03690.HK)$ , $小米集団(01810.HK)$ , ...
1. In the past three years, China's medical beauty industry has undergone earth-shaking changes, and non-surgical products occupy the mainstream
2. The brand is a marketing tool and a social contract for the legal entity to face society. Last year, it began to issue documents on supervising medical aesthetics, focusing on doctors' qualifications, marketing, and the capabilities of three types of ...
$ファイザー(PFE.US)$ $AIM VACCINE(06660.HK)$
$シノバク・バイオテク(SVA.US)$ $復星医薬(02196.HK)$ $Shanghai Fosun Pharmaceutical(600196.SH)$ $CanSino Biologics Inc.(688185.SH)$ $康希諾生物(06185.HK)$ $Walvax Biotechnology(300142.SZ)$ $Chongqing Zhifei Biological Products(300122.SZ)$
$復星医薬(02196.HK)$ Fosun Pharma (02196.HK) yesterday disclosed the third quarterly report data, Q3 company revenue was 10.095 billion yuan, a year-on-year increase of 25.03%; net profit was 1.082 billion yuan, a year-on-year increase of 41.62%.
The growth of Fosun Pharma’s performance is due to alleviation of the pressure of centralized procurement and price reduction of stock varieties. According to the announcement, as of October 24, Fosun Pharma’s Fubitai (mRNA Covid-19 vaccine) has been vaccinated in Hong Kong, Macau and Taiwan over 9.7 million. Agent.
Article excerpted from the U.S. Stock Intelligence Agency
We added fosun Pharmaceutical today.
Because I want to be a butterfly
まだコメントはありません